Spyridon Papapetropoulos is Director at Adamas Pharmaceuticals Inc (ADMS). They have made 1 open-market trade across 1 company since 2021, most recently 2021-11-24.
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $30K since 2021, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ADMS | 20,975 | $172K |
Shares reported on the most recent Form 4, priced at the 2021-06-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ADMS | BUY | 2021-03-11 | 2021-03-15 | $5.06 | $30K | -3.9% | -8.5% | -6.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.